A trial of AGS-003 for kidney cancer that has spread (ADAPT)

This trial is looking at a new therapy called AGS-003 for kidney cancer that has spread.

Doctors may treat advanced kidney cancer with surgery followed by a biological therapy. The most common therapy they use is sunitinib (Sutent).

ASG-003 is made using a piece of your kidney cancer (removed during surgery) and white blood cells called monocytes. The researchers hope that this combination will stimulate your body’s immune system to attack the cancer cells.

In this trial the researchers will compare:

• ASG-003 and sunitinib

• Sunitinib alone

The main aim of this trial is to find out if AGS-003 and sunitinib is better than sunitinib alone for kidney cancer that has spread.